Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation

  Michelle B. Miranda, Robert L. Redner and Daniel E. Johnson

  Mol Cancer Ther December 1 2007 6 (12) 3081-3090; DOI:10.1158/1535-7163.MCT-07-0514

  
  
• Research Articles: Therapeutics, Targets, and Development

  In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches

  Bianca Maria Veneziani, Vittoria Criniti, Carla Cavaliere, Sara Corvigno, Agostina Nardone, Silvia Picarelli, Giampaolo Tortora, Fortunato Ciardiello, Gennaro Limite and Sabino De Placido

  Mol Cancer Ther December 1 2007 6 (12) 3091-3100; DOI:10.1158/1535-7163.MCT-07-0356

  
  
• Research Articles: Therapeutics, Targets, and Development

  Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells

  Clint Mitchell, Maragret A. Park, Guo Zhang, Adly Yacoub, David T. Curiel, Paul B. Fisher, John D. Roberts, Steven Grant and Paul Dent

  Mol Cancer Ther December 1 2007 6 (12) 3101-3112; DOI:10.1158/1535-7163.MCT-07-0561

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inactivation of glycogen synthase kinase-3β contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells

  Zhijie Li, Fei Tan and Carol J. Thiele

  Mol Cancer Ther December 1 2007 6 (12) 3113-3121; DOI:10.1158/1535-7163.MCT-07-0133

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1–targeted tripartite quinone drug delivery system

  Milène Volpato, Nathalie Abou-Zeid, Richard W. Tanner, Lee T. Glassbrook, James Taylor, Ian Stratford, Paul M. Loadman, Mohammed Jaffar and Roger M. Phillips

  Mol Cancer Ther December 1 2007 6 (12) 3122-3130; DOI:10.1158/1535-7163.MCT-07-0519

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antineoplastic agents target the 25-hydroxyvitamin D₃ 24-hydroxylase messenger RNA for degradation: implications in anticancer activity

  Joseph Tan, Prem P. Dwivedi, Paul Anderson, Barbara K. Nutchey, Peter O'Loughlin, Howard A. Morris, Brian K. May, Antonio Ferrante and Charles S. Hii

  Mol Cancer Ther December 1 2007 6 (12) 3131-3138; DOI:10.1158/1535-7163.MCT-07-0427

  
  
• Research Articles: Therapeutics, Targets, and Development

  The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

  Nicola Vannini, Girieca Lorusso, Rosaria Cammarota, Massimo Barberis, Douglas M. Noonan, Michael B. Sporn and Adriana Albini

  Mol Cancer Ther December 1 2007 6 (12) 3139-3146; DOI:10.1158/1535-7163.MCT-07-0451

  
  
• Research Articles: Therapeutics, Targets, and Development

  Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

  Florence Chan, Chongbo Sun, Meg Perumal, Quang-De Nguyen, Vassilios Bavetsias, Edward McDonald, Vanessa Martins, Nicola E. Wilsher, Florence I. Raynaud, Melanie Valenti, Sue Eccles, Robert te Poele, Paul Workman, Eric O. Aboagye and Spiros Linardopoulos

  Mol Cancer Ther December 1 2007 6 (12) 3147-3157; DOI:10.1158/1535-7163.MCT-07-2156

  
  
• Research Articles: Therapeutics, Targets, and Development

  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

  Patrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, Paolo Cappella, Laura Gianellini, Valter Croci, Anna Degrassi, Gemma Texido, Maurizio Rocchetti, Paola Vianello, Luisa Rusconi, Paola Storici, Paola Zugnoni, Claudio Arrigoni, Chiara Soncini, Cristina Alli, Veronica Patton, Aurelio Marsiglio, Dario Ballinari, Enrico Pesenti, Daniele Fancelli and Jürgen Moll

  Mol Cancer Ther December 1 2007 6 (12) 3158-3168; DOI:10.1158/1535-7163.MCT-07-0444

  
  
• Research Articles: Therapeutics, Targets, and Development

  The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells

  Janna Krol, Richard E. Francis, André Albergaria, Andrew Sunters, Andreas Polychronis, R. Charles Coombes and Eric W.-F. Lam

  Mol Cancer Ther December 1 2007 6 (12) 3169-3179; DOI:10.1158/1535-7163.MCT-07-0507

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemosensitization of head and neck cancer cells by PUMA

  Quanhong Sun, Tsukasa Sakaida, Wen Yue, Susanne M. Gollin and Jian Yu

  Mol Cancer Ther December 1 2007 6 (12) 3180-3188; DOI:10.1158/1535-7163.MCT-07-0265

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cell type–dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines

  Jenny Fink, Karl Sanders, Alexandra Rippl, Sylvia Finkernagel, Thomas L. Beckers and Mathias Schmidt

  Mol Cancer Ther December 1 2007 6 (12) 3189-3197; DOI:10.1158/1535-7163.MCT-07-0048

  
  
• Research Articles: Therapeutics, Targets, and Development

  TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth

  Leo Christopher DeRosier, Selwyn M. Vickers, Kurt R. Zinn, Zhi Huang, Wenquan Wang, William E. Grizzle, Jeffrey Sellers, Cecil R. Stockard Jr., Tong Zhou, Patsy G. Oliver, Pablo Arnoletti, Albert F. LoBuglio and Donald J. Buchsbaum

  Mol Cancer Ther December 1 2007 6 (12) 3198-3207; DOI:10.1158/1535-7163.MCT-07-0299

  
  
• Research Articles: Therapeutics, Targets, and Development

  A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells

  Jill Wykosky, Denise M. Gibo and Waldemar Debinski

  Mol Cancer Ther December 1 2007 6 (12) 3208-3218; DOI:10.1158/1535-7163.MCT-07-0200

  
  
• Research Articles: Therapeutics, Targets, and Development

  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis

  Rachel M. Locklin, Ermanno Federici, Belen Espina, Philippa A. Hulley, R. Graham G. Russell and Claire M. Edwards

  Mol Cancer Ther December 1 2007 6 (12) 3219-3228; DOI:10.1158/1535-7163.MCT-07-0275

  
  
• Research Articles: Therapeutics, Targets, and Development

  Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters

  Kazutaka Takagi, Thomas S. Dexheimer, Christophe Redon, Olivier Sordet, Keli Agama, Gilbert Lavielle, Alain Pierré, Susan E. Bates and Yves Pommier

  Mol Cancer Ther December 1 2007 6 (12) 3229-3238; DOI:10.1158/1535-7163.MCT-07-0441

  
  
• Research Articles: Therapeutics, Targets, and Development

  Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation

  Jung Wan Hong, In-Hyun Lee, Young Hak Kwak, Young Taek Park, Ha Chin Sung, Ick Chan Kwon and Hesson Chung

  Mol Cancer Ther December 1 2007 6 (12) 3239-3247; DOI:10.1158/1535-7163.MCT-07-0261

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine–induced urinary bladder carcinogenesis in male ICR mice

  Alpna Tyagi, Komal Raina, Rana P. Singh, Mallikarjuna Gu, Chapla Agarwal, Gail Harrison, L. Michael Glode and Rajesh Agarwal

  Mol Cancer Ther December 1 2007 6 (12) 3248-3255; DOI:10.1158/1535-7163.MCT-07-2006

  
  
• Research Articles: Therapeutics, Targets, and Development

  Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma

  Claudio Scavelli, Giulia Di Pietro, Teresa Cirulli, Mauro Coluccia, Angela Boccarelli, Teresa Giannini, Giuseppe Mangialardi, Raffaello Bertieri, Addolorata Maria Luce Coluccia, Domenico Ribatti, Franco Dammacco and Angelo Vacca

  Mol Cancer Ther December 1 2007 6 (12) 3256-3262; DOI:10.1158/1535-7163.MCT-07-0311

  
  
• Research Articles: Therapeutics, Targets, and Development

  Zoledronic acid inhibits osteosarcoma growth in an orthotopic model

  Crispin R. Dass and Peter F.M. Choong

  Mol Cancer Ther December 1 2007 6 (12) 3263-3270; DOI:10.1158/1535-7163.MCT-07-0546

  
  
• Research Articles: Therapeutics, Targets, and Development

  New inhibitors of ABCG2 identified by high-throughput screening

  Curtis J. Henrich, Robert W. Robey, Heidi R. Bokesch, Susan E. Bates, Suneet Shukla, Suresh V. Ambudkar, Michael Dean and James B. McMahon

  Mol Cancer Ther December 1 2007 6 (12) 3271-3278; DOI:10.1158/1535-7163.MCT-07-0352

  
  
• Research Articles: Therapeutics, Targets, and Development

  The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2

  Suneet Shukla, Chung-Pu Wu, Krishnamachary Nandigama and Suresh V. Ambudkar

  Mol Cancer Ther December 1 2007 6 (12) 3279-3286; DOI:10.1158/1535-7163.MCT-07-0564

  
  
• Research Articles: Therapeutics, Targets, and Development

  Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter

  Chung-Pu Wu, Suneet Shukla, Anna Maria Calcagno, Matthew D. Hall, Michael M. Gottesman and Suresh V. Ambudkar

  Mol Cancer Ther December 1 2007 6 (12) 3287-3296; DOI:10.1158/1535-7163.MCT-07-2005

  
  
• Research Articles: Therapeutics, Targets, and Development

  Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis

  Baohe Zhu, Lei Lu, Weibin Cai, Xia Yang, Chaoyang Li, Zhonghan Yang, Wenhua Zhan, Jian-xing Ma and Guoquan Gao

  Mol Cancer Ther December 1 2007 6 (12) 3297-3306; DOI:10.1158/1535-7163.MCT-06-0798

  
  
• Research Articles: Therapeutics, Targets, and Development

  In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

  Serena Marchetti, Roos L. Oostendorp, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti and Jan H. Schellens

  Mol Cancer Ther December 1 2007 6 (12) 3307-3313; DOI:10.1158/1535-7163.MCT-07-0461

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  James G. Christensen, Helen Y. Zou, Maria E. Arango, Qiuhua Li, Joseph H. Lee, Scott R. McDonnell, Shinji Yamazaki, Gordon R. Alton, Barbara Mroczkowski and Gerrit Los

  Mol Cancer Ther December 1 2007 6 (12) 3314-3322; DOI:10.1158/1535-7163.MCT-07-0365

  
  
• Research Articles: Therapeutics, Targets, and Development

  Mol Cancer Ther December 1 2007 6 (12) 3323-3329; DOI:10.1158/1535-7163.MCT-6-12-ACK